China's chemical api pharmaceutical industry to find leap pedal

in the pharmaceutical market, foreign market listing of new drugs is slowly decreasing, the world's chemical API industry is also moving closer to developing countriesIn such a situation, China's chemical API industry may find a new round of leaping pedals, generic chemical apiwj
Data released by the China Pharmaceutical Industry Information Center show that the global generic drug market has grown at about twice the rate of the drug market since 2000In the United States, a pharmaceutical powerhouse, for example, generic scans accounted for 75 per cent of all prescriptions in 2009, compared with 57 per cent in 2004It can be said that generic drugs have become the main force in the drug marketThis trend will continueData show that between 2012 and 2015, the number of drugs that have expired each year was 111, 120, 132 and 122, respectively, higher than in previous yearswj
From 2009 to 2010, China's pharmaceutical industry entered a platform period, mainly due to China's pharmaceutical industry in the global pharmaceutical industry chain in the low-end API market, especially the bulk API marketIn 2010, a total of 8563 enterprises in China exported API productsThe top 10 export volumes have increased significantly, with 80% of enterprises increasing by more than 20%, reflecting the good business conditions of leading enterprisesHowever, the decline in the average price of 40% of companies' products indicates that leading companies are also facing greater competitive pressurewj
In January, Atvis, the world's third-largest generic drug maker, announced its withdrawal from ChinaSimilarly, most of the international generics giants are feeling unprecedented pressure in ChinaThese factors come from the improvement of China's pharmaceutical level, strict supervision, policy support for domestic generic drugs and many other aspectsHowever, some foreign pharmaceutical companies are not willing to quit, with Bayer's acquisition of Yanhong Pharmaceuticals an example of foreign investment to stay in China's postureIn the future, the domestic generic smaller field will usher in more intense competitionwj
At this stage, China's pharmaceutical industry is showing a good momentum of development, especially the development of generic chemical raw materialsPharmaceutical merchants pointed out that China's generic drug companies should seize this opportunity to enter the development of the industry
WJin the pharmaceutical market, foreign listed new drugs are slowly decreasing, the world's chemical API industry is also moving closer to developing countriesIn such a situation, China's chemical API industry may find a new round of leaping pedals, generic chemical apiwj
Data released by the China Pharmaceutical Industry Information Center show that the global generic drug market has grown at about twice the rate of the drug market since 2000In the United States, a pharmaceutical powerhouse, for example, generic scans accounted for 75 per cent of all prescriptions in 2009, compared with 57 per cent in 2004 It can be said that generic drugs have become the main force in the drug market This trend will continue Data show that between 2012 and 2015, the number of drugs that have expired each year was 111, 120, 132 and 122, respectively, higher than in previous years wj
　　From 2009 to 2010, China's pharmaceutical industry entered a platform period, mainly due to China's pharmaceutical industry in the global pharmaceutical industry chain in the low-end API market, especially the bulk API market In 2010, a total of 8563 enterprises in China exported API products The top 10 export volumes have increased significantly, with 80% of enterprises increasing by more than 20%, reflecting the good business conditions of leading enterprises However, the decline in the average price of 40% of companies' products indicates that leading companies are also facing greater competitive pressure wj
　　In January, Atvis, the world's third-largest generic drug maker, announced its withdrawal from China Similarly, most of the international generics giants are feeling unprecedented pressure in China These factors come from the improvement of China's pharmaceutical level, strict supervision, policy support for domestic generic drugs and many other aspects However, some foreign pharmaceutical companies are not willing to quit, with Bayer's acquisition of Yanhong Pharmaceuticals an example of foreign investment to stay in China's posture In the future, the domestic generic smaller field will usher in more intense competition wj
　　At this stage, China's pharmaceutical industry is showing a good momentum of development, especially the development of generic chemical raw materials Pharmaceutical merchants pointed out that China's generic drug companies should seize this opportunity to make themselves into the development of the industry wWj